NeuroSense Advances PrimeC with Term Sheet Deal and Health Canada Meeting

Introduction to NEUROSENSE THERAPEUTICS LTD

NEUROSENSE THERAPEUTICS LTD (NASDAQ: NRSN) is a clinical-stage biopharmaceutical company founded in 2017 by Alon Ben-Noon. The company focuses on developing combined therapeutic strategies for neurodegenerative diseases, beginning with amyotrophic lateral sclerosis (ALS). Its lead candidate, PrimeC, is an extended-release formulation of ciprofloxacin and celecoxib. PrimeC has been granted orphan drug designation by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with patent protection extending through 2042.

Corporate Structure and Team

The company is headquartered in Cambridge, Massachusetts, and maintains a multidisciplinary team of scientists, clinicians, and industry professionals. Leadership includes CEO Alon Ben-Noon and a board of directors with expertise in neurology, drug development, and regulatory affairs. While exact employee numbers are not publicly disclosed, the organization emphasizes collaboration across research, clinical operations, and regulatory functions.

Neurodegenerative Disease by Milad Fakurian

Developments and News

• December 23, 2024: NeuroSense entered a binding term sheet with a global pharmaceutical company. The agreement includes an upfront payment, funding for the planned Phase 3 trial of PrimeC, regulatory and net-sales milestones, and double-digit royalties in selected territories. Finalization of the definitive agreement is anticipated in Q1 2025.

• April 24, 2025: A letter to shareholders outlined four key areas: ongoing partnership negotiations, Phase 3 trial timelines, Canadian regulatory pathway, and clinical progress. The Phase 2b PARADIGM trial data demonstrated a 33% slowing of ALS progression (p = 0.007) and a 58% improvement in survival rates compared to placebo over 18 months.

• June 26, 2025: NeuroSense completed a pre-New Drug Submission meeting with Health Canada regarding a Notice of Compliance with Conditions (NOC/c) for PrimeC in ALS. Management expects further updates on official meeting minutes and next steps toward early access in Canada.

• July 10, 2025: A corporate video titled “End of Q2/2025 Update” was posted on the company website, discussing clinical milestones, regulatory plans, and investor communications.

• August 1, 2025: A Form 6-K filing with the U.S. Securities and Exchange Commission confirmed the company’s status as a foreign issuer under Rules 13a-16 and 15d-16.

• August 4, 2025: A live event on LinkedIn will feature CEO Alon Ben-Noon and ALS advocate Aaron Lazar, discussing PrimeC’s development path and scientific rationale.

Financial and Strategic Analysis

As of August 1, 2025, NRSN shares closed at $1.25, down 30.56% on NASDAQ, with a trading volume of 583,637. Key metrics from Yahoo Finance include:

• Market capitalization: $30.5 million
• Beta (5Y monthly): 1.64
• Trailing EPS: –$0.54
• Total cash (mrq): $3.38 million
• Total debt/equity (mrq): 2.83%
• Levered free cash flow (ttm): –$7.83 million

The company’s financial position indicates continued R&D expenditures and preparations for a global Phase 3 study slated for mid-2025. Strategic partnerships and potential early commercialization in Canada are aimed at offsetting development costs and enhancing market entry. PrimeC’s orphan drug status and comprehensive patent estate support exclusivity, while planned collaborations could expand distribution in key territories.

Market Position and Industry Context

ALS is an incurable neurodegenerative disease affecting more than 5,000 new patients annually in the U.S., with an economic burden exceeding $1 billion per year. Prevalence is projected to increase by 24% in the U.S. and EU by 2040. NeuroSense’s approach—targeting multiple disease pathways via a fixed-dose combination—aligns with broader trends in neurodegeneration research, where synergy and biomarker modulation are emphasized.

Beyond ALS, the company is advancing Phase 2 trials of a PrimeC-derived candidate for Alzheimer’s disease and preclinical studies of a Parkinson’s therapy. This pipeline diversification positions NeuroSense within the competitive landscape of neurology biotech firms, many of which are exploring multi-modal strategies and microRNA-based interventions.

tl;dr

As of August 1, 2025, NRSN shares trade at $1.25, down 30.56% on NASDAQ. On June 26, 2025, NeuroSense completed a pre-New Drug Submission meeting with Health Canada for PrimeC’s early access. A binding term sheet signed on December 23, 2024, is under negotiation for a definitive agreement in Q1 2025, funding the planned mid-2025 global Phase 3 ALS trial. Upcoming events include an August 4 LinkedIn live discussion on PrimeC’s clinical pathway.